Dieter Ory1, Anna Planas2, Tom Dresselaers3, Willy Gsell3, Andrey Postnov4, Sofie Celen1, Cindy Casteels4, Uwe Himmelreich3, Zeger Debyser5, Koen Van Laere4, Alfons Verbruggen1, Guy Bormans6. 1. Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 2. Department of Brain Ischemia and Neurodegeneration, Institute for Biomedical Research, Barcelona, Spain. 3. Biomedical MRI, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. 4. Nuclear Medicine and Molecular Imaging, University Hospital and KU Leuven, Leuven, Belgium. 5. Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 6. Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: Guy.Bormans@pharm.kuleuven.be.
Abstract
OBJECTIVE: The goal of this study was to measure functional and structural aspects of local neuroinflammation induced by intracerebral injection of lipopolysaccharide (LPS) in rats using TSPO microPET imaging with [(18)F]DPA-714, magnetic resonance imaging (MRI), in vitro autoradiography and immunohistochemistry (IHC) in order to characterize a small animal model for screening of new PET tracers targeting neuroinflammation. METHODS: Rats were injected stereotactically with LPS (50 μg) in the right striatum and with saline in the left striatum. [(18)F]DPA-714 microPET, MRI, in vitro autoradiography and IHC studies were performed at different time points after LPS injection for 1 month. RESULTS: Analysis of the microPET data demonstrated high uptake of the tracer in the LPS injected site with an affected-to-non-affected side-binding potential ratio (BPright-to-left) of 3.0 at 3 days after LPS injection. This BP ratio decreased gradually over time to 0.9 at 30 days after LPS injection. In vitro autoradiography ([(18)F]DPA-714) and IHC (CD68, GFAP and TSPO) confirmed local neuroinflammation in this model. Dynamic contrast enhanced (DCE) MRI demonstrated BBB breakdown near the LPS injection site at day 1, which gradually resolved over time and was absent at 1 month after LPS injection. CONCLUSION: The LPS model is useful for first screening of newly developed tracers because of the easy design and the robust, unilateral inflammatory reaction allowing the use of the contralateral region as control. Additionally, this model can be used to test and follow up the benefits of anti-inflammatory therapies by non-invasive imaging.
OBJECTIVE: The goal of this study was to measure functional and structural aspects of local neuroinflammation induced by intracerebral injection of lipopolysaccharide (LPS) in rats using TSPO microPET imaging with [(18)F]DPA-714, magnetic resonance imaging (MRI), in vitro autoradiography and immunohistochemistry (IHC) in order to characterize a small animal model for screening of new PET tracers targeting neuroinflammation. METHODS:Rats were injected stereotactically with LPS (50 μg) in the right striatum and with saline in the left striatum. [(18)F]DPA-714 microPET, MRI, in vitro autoradiography and IHC studies were performed at different time points after LPS injection for 1 month. RESULTS: Analysis of the microPET data demonstrated high uptake of the tracer in the LPS injected site with an affected-to-non-affected side-binding potential ratio (BPright-to-left) of 3.0 at 3 days after LPS injection. This BP ratio decreased gradually over time to 0.9 at 30 days after LPS injection. In vitro autoradiography ([(18)F]DPA-714) and IHC (CD68, GFAP and TSPO) confirmed local neuroinflammation in this model. Dynamic contrast enhanced (DCE) MRI demonstrated BBB breakdown near the LPS injection site at day 1, which gradually resolved over time and was absent at 1 month after LPS injection. CONCLUSION: The LPS model is useful for first screening of newly developed tracers because of the easy design and the robust, unilateral inflammatory reaction allowing the use of the contralateral region as control. Additionally, this model can be used to test and follow up the benefits of anti-inflammatory therapies by non-invasive imaging.
Authors: Arthur L Brody; Robert Hubert; Ryutaro Enoki; Lizette Y Garcia; Michael S Mamoun; Kyoji Okita; Edythe D London; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern Journal: Neuropsychopharmacology Date: 2017-03-06 Impact factor: 7.853
Authors: K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka Journal: Mol Psychiatry Date: 2017-02-14 Impact factor: 15.992
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: Rheal A Towner; D Saunders; N Smith; W Towler; M Cruz; S Do; J E Maher; K Whitaker; M Lerner; K A Morton Journal: Geroscience Date: 2018-02-07 Impact factor: 7.713
Authors: M Collins Scott; Supinder S Bedi; Scott D Olson; Candice M Sears; Charles S Cox Journal: Expert Opin Ther Targets Date: 2021-06-01 Impact factor: 6.902